Anti-tumor immunity induced by interleukin-12 gene therapy in a metastic model of breast cancer is mediated by natural killer cells

Breast Cancer Research and Treatment

Volumn 60, Issue 2, 2000, Pages 129-134

  Divino, Celia M ^a   Chen, Shu Hsia ^a   Yang, Wen ^a   Thung, Swan ^a   Brower, Steven T ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenoviral vector; Gene therapy; Immunotherapy; Interleukin 12; NK cells

Indexed keywords

INTERLEUKIN 12; VIRUS VECTOR;

ADENOCARCINOMA; ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER MODEL; CONTROLLED STUDY; EFFECTOR CELL; GENE THERAPY; IN VIVO STUDY; INOCULATION; LIVER METASTASIS; LYMPHOCYTE SUBPOPULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR REJECTION; TUMOR VOLUME;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; IMMUNITY, CELLULAR; INTERLEUKIN-12; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0034069130     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006318009608     Document Type: Article

References (31)

1. 1. Miller BA, Feuer EJ, Hankey BF: The significance of the rising incidence of breast cancer in the United States. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. JB Lippincott, Philadelphia, 1994, pp 193-235
2. 2. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-947, 1998
3. 3. Kuerer HM, Newman LA, Buzdar AU et al.: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176(6): 502-509, 1998
4. 4. Wong K, Henderson IC: Management of metastatic breast cancer. World J Surg 18: 98-111, 1994
5. 5. Yeatman TJ: The natural history of locally advanced primary breast carcinoma and metastatic disease. Surg Onc Clin North Am 569-589, 1995
6. 6. Kwong Y-L, Chen S-H, Kosai K et al.: Adenoviral-mediated suicide gene therapy for hepatic metastases of breast cancer. Canc Gene Ther 3(5): 339-344, 1996
7. 7. Yee D, McGuire SE, Brunner N, et al.: Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in a ascites model of human breast cancer. Hum Gene Ther 7: 1251-1257, 1996
8. 8. Tsung K, Meko JB, Peplinski GR, et al.: IL-12 induces T helper 1-directed antitumor response. J Immunol 158: 3359-3365, 1997
9. 9. Banks RE, Patel PM, Selby PJ: Interleukin-12: a new clinical player in cytokine therapy. Br J Canc 71: 280-288, 1995
10. 10. Brunda MJ, Luistro L, Warrier RR, et al.: Antitumor and antimetastatic activity of Interleukin-12 against murine tumors. J Exp Med 178: 1223-1230, 1993
11. 11. Tahara H, Lotze MT: Antitumor effects of Interleukin-12 (IL-12): applications for the immunotherapy and gene therapy for cancer. Gene Ther 2: 96-106, 1996
12. 12. Cesano C, Visonneau S, Clark SC, et al.: Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxicity cells by IL-12. J Immunol 154: 2943-2957, 1993
13. 13. Colombo MP, Vagliani M, Spreafico F, et al.: Amount of Interleukin-12 available at the tumor site is critical for tumor regression. Can Res 56: 2531-2534, 1996
14. 14. Bramson JL, Hitt M, Addison CL, et al.: Direct intratumoral injection of an adenovirus expressing Interleukin-12 induces regression and long lasting immunity that is associated with highly localized expression of Interleukin-12. Hum Gene Ther 7: 1995-2002, 1996
15. 15. Chao TY, Onishi H, Chu TM: Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma. Immunol 70(1): 116-120, 1990
16. 16. Caruso M, Nguyen KP, Kwong YL, et al.: Adenovirus-mediated Interleukin-12 gene therapy for metastatic colon carcinoma. PNAS 93: 11302-11306, 1996
17. 17. Chen L, Chen D, Block E, et al.: Eradication of murine bladder carcinoma by intratumoral injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 159: 351-359, 1997
18. 18. Scott P: Selective differentiation of CD4+ T helper cell subsets. Curr Opin Immunol 5(3): 391-397, 1993
19. 19. Takeda K, Dennert G: Demonstration of MHC Class I-specific cytolytic activity in IL-12 activated NK1+ CD3+ cells and evidence of usage of T and NK cell receptors. Transplantation 58(4): 496-504, 1994
20. 20. Nishimura T, Watanabe K, Lee U, et al.: Phenotypic and functional characteristics of in vivo-induced interleukin-12-activated killer cells. Immunol Lett 48(3): 167-174, 1995
21. 21. Wolf SA, Temple P, Kobayashi M, et al.: Cloning cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immuno 146: 3074-3081, 1991
22. 22. Martinotti A, Stoppacciano A, Vagliani M, et al.: CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with Interleukin-12 genes. Eur J Immunol 25: 137-146, 1995
23. 23. Lamont AG, Adonini L: IL-12: a key cytokine in immune regulation. Immunol Today 17: 214-217, 1996
24. 24. Hashimoto W, Takeda K, Anzai R, et al.: Cytotoxic NK 1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 154: 4333-4340, 1995
25. 25. Takeda K, Seki S, Ogasawara K, et al.: Liver NK 1.1 + CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 156: 3366-3373, 1996
26. 26. Tannenbaum CS, Wicker N, Armstrong D, et al.: Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 156(2): 693-699, 1996
27. 27. Tahara H, Zitvogel L, Storkus WJ, et al.: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral factor. J Immunol 154(12): 6466-6474, 1995
28. 28. Nastala CL, Edington HD, McKinney TG, et al.: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 154(4): 1697-1706, 1994
29. 29. Angiolillo AL, Sgadani and Tosato G: A role for the interferon-inducible protein 10 in inhibition of angiogenesis by Interleukin-12. Ann NY Acad Sci 795: 158-167, 1996
30. 30. Sgadani C, Angiolillio AL, Tosato G: Inhibition of angiogenesis by Interleukin-12 is mediated by interferon-inducible protein 10. Blood 87(9): 3877-3882, 1996
31. 31. Pham-Nguyen KB, Yang W. Saxena R: The role of NK and T cells in IL-12 induced antitumor response against hepatic colon carcinoma. Intl J Canc 81: 813-819, 1999